Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial

@article{Corrigan2004EffectivenessOT,
  title={Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial},
  author={M. Corrigan and C. Gallen and M. Bonura and K. Merchant and Sonepiprazole Study Group},
  journal={Biological Psychiatry},
  year={2004},
  volume={55},
  pages={445-451}
}
  • M. Corrigan, C. Gallen, +2 authors Sonepiprazole Study Group
  • Published 2004
  • Psychology, Medicine
  • Biological Psychiatry
  • BACKGROUND Selective localization of dopamine D(4) receptors in the prefrontal cortex and preferential affinity of clozapine for the dopamine D(4) receptor over the D(2) receptor led to the hypothesis that the superior efficacy of clozapine may be mediated via blockade of the D(4) receptor. This hypothesis was tested by evaluating sonepiprazole, a selective D(4) dopamine antagonist, in schizophrenia patients. METHODS We treated 467 hospitalized schizophrenia patients with scores of > or = 60… CONTINUE READING
    93 Citations
    Role of dopamine D(2) receptors for antipsychotic activity.
    • 107
    Neurochemical arguments for the use of dopamine D4 receptor stimulation to improve cognitive impairment associated with schizophrenia
    • 11
    Return of D4 Dopamine Receptor Antagonists in Drug Discovery.
    • 15

    References

    SHOWING 1-10 OF 22 REFERENCES
    Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.
    • 91
    Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia
    • A. Murray, T. Hyde, +5 authors J. Kleinman
    • Chemistry, Medicine
    • The Journal of neuroscience : the official journal of the Society for Neuroscience
    • 1995
    • 182
    • PDF
    Dopamine D4 receptors elevated in schizophrenia
    • 612